The Global Multiple Sclerosis Drugs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, supply chain analysis, competitive landscape, and market composition analysis.
The global multiple sclerosis drugs market size was estimated to be US$ 24.6 billion and expected to reach 49.3 billion by 2030 at a CAGR of 7.5%. Multiple sclerosis is a chronic, inflammatory, autoimmune nervous system disorder where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions, and affects the spinal cord, and the (CNS) central nervous system, especially the communication between the brain and other areas of the body resulting in loss of balance, coordination and compromised vision. Multiple sclerosis (MS) is basically an immune-mediated, demyelinating illness which damages the insulating covers of the nerve cells in the brain and spinal cord (CNS). The disease can result in long term disability. It is characterized by inflammation, demyelination, and degenerative changes such as progressive brain and neuroaxonal, loss spinal cord atrophy, among others.
